Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

The emerging quest for the optimal angiostatic combination therapy: Figure 1

(2014) Arjan W. Griffioen et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients

(2014) Anna Spreafico et al.   INVESTIGATIONAL NEW DRUGS

Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization

(2014) Andrea Weiss et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

(2014) P. Y. Wen et al.   NEURO-ONCOLOGY

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2014) S. Misale et al.   Science Translational Medicine

In vivo anti-tumor activity of the organometallic ruthenium(ii)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas

(2014) Andrea Weiss et al.   Chemical Science

Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity

(2014) Zenita Adhireksan et al.   Nature Communications

Bayesian Active Learning for Drug Combinations

(2013) Mijung Park et al.   IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

(2013) Julie E. Bauman et al.   ORAL ONCOLOGY

Evolutionary dynamics of cancer in response to targeted combination therapy

(2013) Ivana Bozic et al.   eLife

CD34 marks angiogenic tip cells in human vascular endothelial cell cultures

(2012) Martin J. Siemerink et al.   ANGIOGENESIS

Understanding resistance to combination chemotherapy

(2012) Justin R. Pritchard et al.   DRUG RESISTANCE UPDATES

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1

(2012) J R van Beijnum et al.   ONCOGENE

Mechanism-independent method for predicting response to multidrug combinations in bacteria

(2012) Kevin Wood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

VEGF Inhibition, Hypertension, and Renal Toxicity

(2012) Suzanne R. Hayman et al.   Current Oncology Reports

Systematic quantitative characterization of cellular responses induced by multiple signals

(2011) Ibrahim Al-Shyoukh et al.   BMC Systems Biology

Volociximab in cancer

(2011) Salah Almokadem et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?

(2011) Anne Q. Reuwer et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Control of Kaposi's Sarcoma-Associated Herpesvirus Reactivation Induced by Multiple Signals

(2011) Fuqu Yu et al.   PLoS One

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status

(2011) Pankaj Bhargava et al.   Current Oncology Reports

An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells

(2011) Hideaki Tsutsui et al.   Nature Communications

Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane

(2010) Patrycja Nowak-Sliwinska et al.   ANGIOGENESIS

Drug Resistance, Epigenetics, and Tumor Cell Heterogeneity

(2010) T. Hoey   Science Translational Medicine

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2009) Darren R. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting mTOR: Something Old, Something New

(2009) K. Garber   JNCI-Journal of the National Cancer Institute

Synergistic drug combinations tend to improve therapeutically relevant selectivity

(2009) Joseph Lehár et al.   NATURE BIOTECHNOLOGY

Systems approaches and algorithms for discovery of combinatorial therapies

(2009) Jacob D. Feala et al.   Wiley Interdisciplinary Reviews-Systems Biology and Medicine

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs

(2008) R Bianco et al.   BRITISH JOURNAL OF CANCER

Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis

(2008) M. Martin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm

(2008) Pak Kin Wong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Search Algorithms as a Framework for the Optimization of Drug Combinations

(2008) Diego Calzolari et al.   PLoS Computational Biology